financetom
Business
financetom
/
Business
/
NOV Offers Upside From Improved Offshore and Short-Cycle Activity but Better Alternatives Exist, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NOV Offers Upside From Improved Offshore and Short-Cycle Activity but Better Alternatives Exist, RBC Says
Apr 14, 2026 8:37 AM

11:24 AM EDT, 04/14/2026 (MT Newswires) -- NOV (NOV) offers potential upside from improvement in offshore and short-cycle activity, but there are more attractive ways to play these themes at present, RBC Capital Markets said Tuesday in a note.

Major tailwinds include improved offshore activity in the second half supporting rig aftermarket revenue, ongoing progress on the Brazil flexible pipe, and improvement in the Middle East drilling and completion activity. NOV's energy equipment business is also executing on a $4.4 billion backlog, providing short-term financial stability, according to the note.

NOV generates about 15% to 20% of its revenue from the Middle East, exposing it to the Iran war, while its product-based business faces inflationary pressure from higher transportation costs, the brokerage said.

RBC raised its 2026 US land rig count estimate to 544 active rigs and said it would seek pressure pumpers for the most torque, in terms of utilization and pricing. Similarly, deescalation in the Middle East will likely benefit service-based companies more, the firm added.

RBC's Q1 EBITDA estimate of $207 million is below the Street estimate of $210 million and NOV's guidance of $200 million to $225 million. The mid- to longer-term outlook is also not differentiated versus oilfield services peers, the brokerage said.

RBC downgraded NOV to sector perform from outperform, with a price target of $21.

Price: 19.23, Change: -0.40, Percent Change: -2.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CoreWeave Insider Sold Shares Worth $5,567,083, According to a Recent SEC Filing
CoreWeave Insider Sold Shares Worth $5,567,083, According to a Recent SEC Filing
Apr 13, 2026
03:48 AM EDT, 04/13/2026 (MT Newswires) -- Michael N Intrator, 10% Owner, Director, Chief Executive Officer and President, on April 08, 2026, sold 62,399 shares in CoreWeave ( CRWV ) for $5,567,083. Following the Form 4 filing with the SEC, Intrator has control over a total of 5,466,501 Class A common shares of the company, with 5,466,501 shares held directly....
Aehr Test Systems Insider Sold Shares Worth $1,081,856, According to a Recent SEC Filing
Aehr Test Systems Insider Sold Shares Worth $1,081,856, According to a Recent SEC Filing
Apr 13, 2026
03:49 AM EDT, 04/13/2026 (MT Newswires) -- Donald P. Richmond II, Chief Technology Officer, on April 09, 2026, sold 15,751 shares in Aehr Test Systems ( AEHR ) for $1,081,856. Following the Form 4 filing with the SEC, Richmond has control over a total of 199,245 common shares of the company, with 199,245 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1040470/000104047026000085/xslF345X05/primary_01.xml ...
Aehr Test Systems Insider Sold Shares Worth $2,373,250, According to a Recent SEC Filing
Aehr Test Systems Insider Sold Shares Worth $2,373,250, According to a Recent SEC Filing
Apr 13, 2026
03:50 AM EDT, 04/13/2026 (MT Newswires) -- Geoffrey Gates Scott, Director, on April 09, 2026, sold 35,000 shares in Aehr Test Systems ( AEHR ) for $2,373,250. Following the Form 4 filing with the SEC, Scott has control over a total of 218,550 common shares of the company, with 52,864 shares held directly and 165,686 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1040470/000104047026000079/xslF345X05/primary_01.xml...
Apogee Therapeutics Insider Sold Shares Worth $1,651,664, According to a Recent SEC Filing
Apogee Therapeutics Insider Sold Shares Worth $1,651,664, According to a Recent SEC Filing
Apr 13, 2026
03:50 AM EDT, 04/13/2026 (MT Newswires) -- Michael Thomas Henderson, Director, Chief Executive Officer, on April 08, 2026, sold 20,000 shares in Apogee Therapeutics ( APGE ) for $1,651,664. Following the Form 4 filing with the SEC, Henderson has control over a total of 1,132,987 common shares of the company, with 1,132,987 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1974640/000110465926042155/xslF345X05/tm2611503-1_4seq1.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved